The cardioprotector dexrazoxane augments therapeutic efficacy of mitoxantrone in experimental autoimmune encephalomyelitis

Clinical and Experimental Immunology

Volumn 135, Issue 1, 2004, Pages 49-55

  Weilbach, F X ^a,b   Chan, A ^a   Toyka, K V ^a   Gold, R ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b NONE   (Germany)

Author keywords

Chelator; Dexrazoxane; Experimental autoimmune encephalomyelitis; Free radical; Iron; Mitoxantrone; Multiple sclerosis

Indexed keywords

ANTHRACYCLINE DERIVATIVE; GELATINASE A; GELATINASE B; IMMUNOSUPPRESSIVE AGENT; IRON CHELATING AGENT; MITOXANTRONE; MYELIN BASIC PROTEIN; RAZOXANE;

ACTIVE IMMUNIZATION; ADOPTIVE TRANSFER; ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG SCREENING; ENZYME ACTIVITY; EX VIVO STUDY; EXPERIMENT; FEMALE; HEART PROTECTION; INFLAMMATORY INFILTRATE; LYMPH NODE CELL; LYMPHOCYTE TRANSFER; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; RAT; SPINAL CORD DISEASE; T LYMPHOCYTE;

ANIMALS; APOPTOSIS; CARDIOTONIC AGENTS; CHELATING AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; GELATINASES; IMMUNOSUPPRESSIVE AGENTS; LYMPH NODES; LYMPHOCYTE ACTIVATION; MACROPHAGES; MITOXANTRONE; RATS; RATS, INBRED LEW; RAZOXANE; SPINAL CORD; T-LYMPHOCYTES;

EID: 0347319058     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2004.02344.x     Document Type: Article

References (22)

1. Hartung HP, Gonsette R, Konig N et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002; 360:2018-25.
2. Baker D, O'Neill JK, Davison AN et al. Control of immune-mediated disease of the central nervous system requires the use of a neuroactive agent: elucidation by the action of mitoxantrone. Clin Exp Immunol 1992; 90:124-8.
3. Watson CM, Davison AN, Baker D et al. Suppression of demyelination by mitoxantrone. Int J Immunopharmacol 1991; 13:923-30.
4. Lublin FD, Lavasa M, Viti C et al. Suppression of acute and relapsing experimental allergic encephalomyelitis with mitoxantrone. Clin Immunol Immunopathol 1987; 45:122-8.
5. Ridge SC, Sloboda AE, McReynolds RA et al. Suppression of experimental allergic encephalomyelitis by mitoxantrone. Clin Immunol Immunopathol 1985; 35:35-42.
6. Fidler JM, DeJoy SQ, Smith FD et al. Selective immunomodulation by the antineoplastic agent mitoxantrone. II. Nonspecific adherent suppressor cells derived from mitoxantrone-treated mice. J Immunol 1986; 136:2747-54.
7. Fidler JM, DeJoy SQ, Gibbons J Jr. Selective immunomodulation by the antineoplastic agent mitoxantrone. I. Suppression of B lymphocyte function. J Immunol 1986; 137:727-32.
8. Mather FJ, Simon RM, Clark GM et al. Cardiotoxicity in patients treated with mitoxantrone: Southwest Oncology Group phase II studies. Cancer Treat Rep 1987; 71:609-13.
9. Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf 2000; 22:263-302.
10. Gold R, Giegerich G, Hartung HP et al. T-cell receptor (TCR) usage in Lewis rat experimental autoimmune encephalomyelitis: TCR beta-chain-variable- region V beta 8.2-positive T cells are not essential for induction and course of disease. Proc Natl Acad Sci USA 1995; 92:5850-4.
11. Zettl UK, Gold R, Toyka KV et al. In situ demonstration of T cell activation and elimination in the peripheral nervous system during experimental autoimmune neuritis in the Lewis rat. Acta Neuropathol 1996; 91:360-7.
12. Gold R, Schmied M, Giegerich G et al. Differentiation between cellular apoptosis and necrosis by the combined use of in situ tailing and nick translation techniques. Lab Invest 1994; 71:219-25.
13. Brown PD, Levy AT, Margulies IM et al. Independent expression and cellular processing of Mr 72,000 type IV collagenase and interstitial collagenase in human tumorigenic cell lines. Cancer Res 1990; 50:6184-91.
14. Chan A, Reiter R, Wiese S et al. Plasma membrane phospholipid asymmetry precedes DNA fragmentation in different apoptotic cell models. Histochem Cell Biol 1998; 110:553-8.
15. Narang PK, Hochester H, Reynolds RD et al. Does the cardioprotectant dexrazoxane (DZR) affect doxorubicin (DOX) kinetics/ dynamics? Proc Am Soc Clin Oncol 1992; 11:126.
16. Hileti D, Panayiotidis P, Hoffbrand AV. Iron chelators induce apoptosis in proliferating cells. Br J Haematol 1995; 89:181-7.
17. van Reyk DM, Sarel S, Hunt NH. In vitro effects of three iron chelators on mitogen-activated lymphocytes: identification of differences in their mechanisms of action. Int J Immunopharmacol 1992; 14:925-32.
18. Bowern N, Ramshaw IA, Clark IA et al. Inhibition of autoimmune neuropathological process by treatment with an iron-chelating agent. J Exp Med 1984; 160:1532-43.
19. Quesada AR, Barbacid MM, Mira E et al. Evaluation of fluorometric and zymographic methods as activity assays for stromelysins and gelatinases [published erratum appears in Clin Exp Metastasis 1997 May; 15: 339-40]. Clin Exp Metastasis 1997; 15:26-32.
20. Pedchenko TV, LeVine SM. Desferrioxamine suppresses experimental allergic encephalomyelitis induced by MBP in SJL mice. J Neuroimmunol 1998; 84:188-97.
21. Willenborg DO, Bowern NA, Danta G et al. Inhibition of allergic encephalomyelitis by the iron chelating agent desferrioxamine: differential effect depending on type of sensitizing encephalitogen. J Neuroimmunol 1988; 17:127-35.
22. Wiseman LR, Spencer CM. Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy. Drugs 1998; 56:385-403.